|
|
Publication
|
| Title of Article |
Effectiveness of Anti-Viral Medications for Treatment of Chronic Hepatitis C: A Retrospective Study in a Tertiary Care Hospital in Northeast Thailand |
| Date of Acceptance |
7 June 2023 |
| Journal |
| Title of Journal |
วารสารวิจัย มข. (ฉบับบัณฑิตศึกษา) |
| Standard |
TCI |
| Institute of Journal |
บัณฑิตวิทยาลัย มหาวิทยาลัยขอนแก่น |
| ISBN/ISSN |
2672-9636(Online) |
| Volume |
24 |
| Issue |
2 |
| Month |
April to June |
| Year of Publication |
2024 |
| Page |
|
| Abstract |
ABSTRACT
The objectives of the study were to assess the effectiveness of the anti-viral medications for treatment of chronic hepatitis C virus (HCV) infection and the factors associated with the effectiveness. The method was a retrospective study conducted in outpatients treated with anti-HCV medications at Khon Kaen hospital during January 1st 2019 to December 31st 2020. Demographic, social history, and medical history data were collected from medical records. Effectiveness was determined as an undetectable HCV RNA in the blood (<25 IU/mL) at 12 weeks post-treatment (Sustained Virologic Response; SVR12) and analyzed using descriptive analysis. Multivariate logistic regression analysis was used to identify factors associated with the effectiveness. The results showed that from a total of 160 patients included to the study, HCV genotypes 1, 3, 6 were found in 38.8, 43.1, and 18.1%, respectively. Majority of the patients were male (76.2%) and the average age was 50.5years. There were 75 patients (46.9%) having cirrhosis, 16 (10.0%) having HIV infection, and 22 (13.8%) having a previous treatment failure. Overall, SVR12 was achieved in 153 patients (95.6%). The SVR12 rate of genotype 3 was 98.6%. Patients with HCV genotype 1 achieved SVR12 at 95.7% in non-cirrhosis group and 94.9% in cirrhosis group. Similarly, SVR12 of genotype 6 patients was achieved in 100% and 84.2% in non-cirrhosis and cirrhosis group, respectively. Three significant factors, including female gender (adjusted odds ratio (OR) 0.11; 95% CI 0.02-0.85), co-infection with HIV (OR 0.06; 95% CI 0.01-0.53) and genotype 6 with cirrhosis (OR 0.04; 95% CI 0.01-0.45), were negatively associated with treatment effectiveness. In conclusions, anti-HCV treatment was effective for genotype 1, 3, and 6 infections. The patients with no cirrhosis were likely to have better respond to the anti-HCV treatment. Female gender, co-infection with HIV, and genotype 6 with cirrhosis were significant factors negatively affecting effectiveness of HCV treatment.
|
| Keyword |
Hepatitis C virus infection, anti-viral medications, Sustained Virologic Response |
| Author |
|
| Reviewing Status |
มีผู้ประเมินอิสระ |
| Status |
ได้รับการตอบรับให้ตีพิมพ์ |
| Level of Publication |
นานาชาติ |
| citation |
true |
| Part of thesis |
true |
| Attach file |
|
| Citation |
0
|
|
|
|
|
|
|
|
|
Journal Publication
ไทย